alecensa capsule 150mg (アレセンサカプセル150mg)
chugai pharmaceutical co., ltd. - alectinib hydrochloride - white to yellowish white, major axis: approximately 19 mm
lorviqua
pfizer europe ma eeig - lorlatinib - carcinoma, non-small-cell lung - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor.lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.
alecensa capsules hard
f. hoffmann-la roche ag - alectnib (alectinib hydrochloride) - capsules hard - 150mg
alecensa capsules hard
f. hoffmann-la roche ltd - alectnib (alectinib hydrochloride) - capsules hard - 150mg
lorviqua 25 mg film-coated tablets
pfizer (malaysia) sdn. bhd. - lorlatinib -
lorviqua film-coated tablet 100mg
pfizer private limited - lorlatinib - tablet, film coated - lorlatinib 100 mg
lorviqua film-coated tablet 25mg
pfizer private limited - lorlatinib - tablet, film coated - lorlatinib 25mg
lorviqua 100 mg film-coated tablets
pfizer (malaysia) sdn. bhd. - lorlatinib -
lorbrena tablet
pfizer canada ulc - lorlatinib - tablet - 25mg - lorlatinib 25mg - antineoplastic agents
lorbrena tablet
pfizer canada ulc - lorlatinib - tablet - 100mg - lorlatinib 100mg - antineoplastic agents